IGF::OT::IGF - PAUL C. ANDERSON MEDICINAL CHEMISTRY CONSULTANT SUPPORT SERVICES

代表16个NIH研究所和中心的NIH神经科学研究蓝图宣布了一项针对神经治疗学的重大挑战，以解决神经系统疾病有效药物的缺乏问题。为了迎接这一重大挑战，NIH蓝图正在开创一种新的药物开发模式，一个将行业药物开发专业知识与创新的疾病生物学相结合的网络，这是NIH资助研究的优势。蓝图神经治疗网络将作为一个虚拟药房(http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm).运行具有令人信服的治疗原理和药物开发项目的起始材料的神经科学研究人员(主要研究人员)将与设计和指导药物开发计划的高级、行业经验丰富的顾问相匹配。主要研究人员将进行生物活性分析和生物学工作，合同研究组织(CRO)将实施所有其他药物开发活动，这些组织将由NIH通过单独的合同确定和资助。参与项目的首席调查员、顾问、NIH工作人员和CRO工作人员将组成一个领导开发团队(LDT)。 这项研究是NIH帮助结束成瘾长期(Hear)倡议的一部分，该倡议旨在加快科学解决方案，以了解疼痛的基础并加强临床疼痛管理。这是该计划的一部分，该计划为各种疼痛状况建立了新的治疗选择，以提高生活质量和减少阿片类药物依赖。该项目研究范围广泛的疼痛状况，包括慢性重叠疼痛状况、慢性肌肉骨骼疼痛、围手术期疼痛和膝骨性关节炎。

The NIH Blueprint for Neuroscience Research, representing sixteen NIH Institutes and Centers, announced a Grand Challenge for Neurotherapeutics to address the paucity of effective drugs for disorders of the nervous system. To meet this Grand Challenge, the NIH Blueprint is pioneering a new model for drug development a network that integrates industry drug development expertise with the innovative disease biology that is the strength of NIH-funded research. The Blueprint Neurotherapeutics Network will operate as a virtual pharma (http://neuroscienceblueprint.nih.gov/bpdrugs/index.htm). Neuroscience researchers (principal investigators) with a compelling therapeutic rationale and starting materials for a drug development project will be matched with senior-level, industry-seasoned consultants who will design and direct the drug development plan. The principal investigators will conduct the bioactivity assays and biological work, and Contracted Research Organizations (CROs), which will be identified and funded by NIH through separate contracts, will implement all other drug development activities. The principal investigator, consultants, NIH staff, and CRO staff engaged in a project will constitute a Lead Development Team (LDT). This study is part of the NIH’s Helping to End Addiction Long-term (HEAL) initiative to speed scientific solutions to understand the basis of pain and enhance clinical pain management. It’s part of the program that establishes novel treatment options for a variety of pain conditions to improve quality of life and reduce opioid dependency. The program studies a broad range of pain conditions, including chronic overlapping pain conditions, chronic musculoskeletal pain, perioperative pain, and knee osteoarthritis.